Optimized targeting of polyethylene glycol-stabilized anti-intercellular adhesion molecule 1 oligonucleotide/lipid particles to liver sinusoidal endothelial cells

Molecular Pharmacology

Volumn 67, Issue 3, 2005, Pages 883-890

  Bartsch, Martin ^a   Weeke Klimp, Alida H ^a   Morselt, Henriëtte W M ^a   Kimpfler, Andrea ^c   Ásgeirsdóttir, Sigridur A ^b   Schubert, Rolf ^c   Meijer, Dirk K F ^b   Scherphof, Gerrit L ^a   Kamps, Jan A A M ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALCOHOL; AMPHIPHILE 1,2 DIOLEOYL 3 TRIMETHYL AMMONIUM PROPANE; ANTISENSE OLIGONUCLEOTIDE; INTERCELLULAR ADHESION MOLECULE 1; LIPID; MACROGOL; MALEIMIDE; MESSENGER RNA; PROPANE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; LIPID BILAYER; LIVER SINUSOID; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; RAT; REAL TIME POLYMERASE CHAIN REACTION; TARGET CELL;

ANIMALS; CELL LINE; ENDOTHELIAL CELLS; FATTY ACIDS, MONOUNSATURATED; INTERCELLULAR ADHESION MOLECULE-1; KUPFFER CELLS; LIVER; OLIGONUCLEOTIDES, ANTISENSE; POLYETHYLENE GLYCOLS; QUATERNARY AMMONIUM COMPOUNDS; RATS; RATS, INBRED STRAINS;

EID: 14944376965     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.004523     Document Type: Article

References (38)

1. Allen TM and Cullis PR (2004) Drug delivery systems: entering the mainstream. Science (Wash DC) 303:1818-1822.
2. Bally MB, Harvie P, Wong FM, Kong S, Wasan EK, and Reimer DL (1999) Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev 38:291-315.
3. Bartsch M, Weeke-Klimp AH, Meijer DKF, Scherphof GL, and Kamps JAAM (2002) Massive and selective delivery of lipid-coated cationic lipoplexes of oligonucleotides targeted in vivo to hepatic endothelial cells. Pharm Res (NY) 19:676-680.
4. Biessen EA, Vietsch H, Kuiper J, Bijsterbosch MK, and Berkel TJ (1998) Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol Pharmacol 53:262-269.
5. Bijsterbosch MK, Manoharan M, Rump ET, de Vrueh RL, Van Veghel R, Tivel KL, Biessen EA, Bennett CF, Cook PD, and Van Berkel TJ (1997) In vivo fate of phosphorothioate antisense oligodeoxynucleotides: predominant uptake by scavenger receptors on endothelial liver cells. Nucleic Acids Res 25:3290-3296.
6. Bijsterbosch MK, Ziere GJ, and Van Berkel TJ (1989) Lactosylated low density lipoprotein: a potential carrier for the site-specific delivery of drugs to Kupffer cells. Mol Pharmacol 36:484-489.
7. Böttcher CJF, Van Gent CM, and Pries C (1961) A rapid and sensitive sub-micro phosphorus determination. Analytica Chimica Acta 24:204-205.
8. Chirila TV, Rakoczy PE, Garrett KL, Lou X, and Constable IJ (2002) The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides. Biomaterials 23:321-342.
9. Daemen T, Velinova M, Regts J, de Jager M, Kalicharan R, Donga J, van der Want JJ, and Scherphof GL (1997) Different intrahepatic distribution of phosphatidyl-glycerol and phosphatidylserine liposomes in the rat. Hepatology 26:416-423.
10. Dass CR (2002) Liposome-mediated delivery of oligodeoxynucleotides in vivo. Drug Deliv 9:169-180.
11. Derksen JTP and Scherphof GL (1985) An improved method for the covalent coupling of proteins to liposomes. Biochim Biophys Acta 814:151.
12. Frederik PM, Bomans PHH, and Stuart MCA (1993) Matrix effects and the induction of mass loss or bubbling by the electron beam in vitrified hydrated specimens. Ultramicroscopy 48:107-119.
13. Garcia-Chaumont C, Seksek O, Grzybowska J, Borowski E, and Bolard J (2000) Delivery systems for antisense oligonucleotides. Pharmacol Ther 87:255-277.
14. Graham MJ, Crooke ST, Lemonidis KM, Gaus HJ, Templin MV, and Crooke RM (2001) Hepatic distribution of a phosphorothioate oligodeoxynucleotide within rodents following intravenous administration. Biochem Pharmacol 62:297-306.
15. Jansen RW, Molema G, Harms G, Kruijt JK, Van Berkel TJ, Hardonk MJ, and Meijer DK (1991) Formaldehyde treated albumin contains monomeric and polymeric forms that are differently cleared by endothelial and kupffer cells of the liver: evidence for scavenger receptor heterogeneity. Biochem Biophys Res Commun 180:23-32.
16. Kaiser N, Kimpfler A, Massing U, Burger AM, Fiebig HH, Brandi M, and Schubert R (2003) 5-Fluorouracil in vesicular phospholipid gels for anticancer treatment: entrapment and release properties. Int J Pharm 256:123-131.
17. Kamps JAAM, Morselt HW, Swart PJ, Meijer DKF, and Scherphof GL (1997) Massive targeting of liposomes, surface-modified with anionized albumins, to hepatic endothelial cells. Proc Natl Acad Sci USA 94:11681-11685.
18. Kamps JAAM and Scherphof GL (2003) Liposomes in biological systems, in Liposomes, a Practical Approach (Torchilin VP and Weissig V eds) pp 267-288, Oxford University Press, Oxford.
19. Kamps JAAM, Swart PJ, Morselt HW, Pauwels R, De Bethune MP, De Clercq E, Meijer DKF, and Scherphof GL (1996) Preparation and characterization of conjugates of (modified) human serum albumin and liposomes: drug carriers with an intrinsic anti-HIV activity. Biochim Biophys Acta 1278:183-190.
20. Keidar S, Kaplan M, and Aviram M (1996) Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arteriascler Thromb Vasc Biol 16:97-105.
21. Kurreck J (2003) Antisense technologies. Improvement through novel chemical modifications. Eur J Biochem 270:1628-1644.
22. Leonetti C, Biroccio A, Benassi B, Stringaro A, Stoppacciaro A, Semple SC, and Zupi G (2001) Encapsulation of C-myc antisense oligodeoxynucleotides in lipid particles improves antitumoral efficacy in vivo in a human melanoma line. Cancer Gene Ther 8:459-468.
23. Lucas B, Van Rompaey E, Kemaut K, Sanders N, De Smedt SC, and Demeester J (2004) On the biological activity of anti-ICAM-1 oligonucleotides complexed to non-viral carriers. J Control Release 96:207-219.
24. Matteucci MD and Wagner RW (1996) In pursuit of antisense. Nature (Lond) 384:20-22.
25. Opalinska JB and Gewirtz AM (2002) Nucleic-acid therapeutics: basic principles and recent applications. Nat Rev Drug Discov 1:503-514.
26. Peterson GL (1977) A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83:346-356.
27. Pirollo KF, Rait A, Sleer LS, and Chang EH (2003) Antisense therapeutics: from theory to clinical practice. Pharmacol Ther 99:55-77.
28. Ruetten H, Thiemermann C, and Perretti M (1999) Upregulation of ICAM-1 Expression on J774.2 macrophages by endotoxin involves activation of NF-KappaB but not protein tyrosine kinase: comparison to induction of INOS. Mediators Inflamm 8:77-84.
29. Schatzlein AG (2001) Non-viral vectors in cancer gene therapy: principles and progress. Anticancer Drugs 12:275-304.
30. Scherer LJ and Rossi JJ (2003) Approaches for the sequence-specific knockdown of MRNA. Nat Biotechnol 21:1457-1465.
31. Scherphof GL, Kamps JAAM, and Koning GA (1997) In vivo targeting of surface-modified liposomes to metastatically growing colon carcinoma cells and sinusoidal endothelial cells in rat liver. J Liposome Res 7:419-432.
32. Semple SC, Klimuk SK, Harasym TO, Dos SN, Ansell SM, Wong KF, Maurer N, Stark H, Cullis PR, Hope MJ, et al. (2001) Efficient encapsulation of antisense oligonucleotides in lipid vesicles using ionizable aminolipids: formation of novel small multilamellar vesicle structures. Biochim Biophys Acta 1510:152-166.
33. Stuart DD, Semple SC, and Allen TM (2004) High efficiency entrapment of antisense oligonucleotides in liposomes. Methods Enzymol 387:171-188.
34. Van Berkel TJ, De Rijke YB, and Kruijt JK (1991) Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells. J Biol Chem 266:2282-2289.
35. Zelphati O and Szoka FC Jr (1996) Mechanism of oligonucleotide release from cationic liposomes. Proc Natl Acad Sci USA 93:11493-11498.
36. Zhang YP, Sekirov L, Saravolac EG, Wheeler JJ, Tardi P, Clow K, Leng E, Sun R, Cullis PR, and Scherrer P (1999) Stabilized plasmid-lipid particles for regional gene therapy: formulation and transfection properties. Gene Ther 6:1438-1447.
37. Zhou W, Yuan X, Wilson A, Yang L, Mokotoff M, Pitt B, and Li S (2002) Efficient intracellular delivery of oligonucleotides formulated in folate receptor-targeted lipid vesicles. Bioconjug Chem 13:1220-1225.
38. Zhu FG, Reich CF, and Pisetsky DS (2002) Inhibition of murine macrophage nitric oxide production by synthetic oligonucleotides. J Leukoc Biol 71:686-694.